Effect of Lanolin and Breastmilk in the Treatment of Sore and Damaged Nipples in Breastfeeding Women
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04153513 |
Recruitment Status :
Completed
First Posted : November 6, 2019
Last Update Posted : February 16, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breastfeeding | Drug: Lanolin Other: Mother's milk | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 206 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Investigator) |
Masking Description: | Participants will be randomly assigned to two study groups. An envelope containing a note, "mother's milk group" or "lanolin group" will be randomly distributed among women by a midwife who is not a part of the study. The participants will know which group they belong to. A single blind masking will be used during telephone data collection on day three and seven of treatment. |
Primary Purpose: | Prevention |
Official Title: | Comparison of the Effect of Lanolin and Breastmilk in the Treatment of Sore and Damaged Nipples in Breastfeeding Women- a Randomized Controlled Trial |
Actual Study Start Date : | January 1, 2019 |
Actual Primary Completion Date : | September 30, 2020 |
Actual Study Completion Date : | September 30, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Lanolin |
Drug: Lanolin
Lanolin will be applied by hand in a thin layer to the nipple and areola after every breast feed (approximately every 2 to 3 hours) for a maximum of 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days). |
Active Comparator: Mother's milk |
Other: Mother's milk
After each breast feed (approximately every 2 to 3 hours), a few drops of breast milk will be applyed to the nipple and areola by hand and allow them to air dry. The treatment will last for up to 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days). |
- Change in nipple pain severity [ Time Frame: baseline, 3 and 7 days post randomization ]An abbreviated version of the McGill Questionnaire (SF-MPQ) will be used to assess the intensity of nipple pain. For the assessment of the current intensity of pain in the nipples will be used subcategories SF-MPQ, the current assessment of pain (PPI). It consists of a verbal scoring scale with values from 0 to 5, 0= No pain, 1= Mild, 2 = Discomforting, 3= Distressing, 4= Horrible, 5= Excruciating
- Nipple damage change [ Time Frame: baseline, 3 and 7 days post randomization ]
The baseline assessment of nipple damage will be performed by a validated Nipple Trauma Score (NST). The assessment is performed on scales from 0 to 5 where 0 = no macroscopically visible changes in the skin, 1 = erythema or edema or a combination of both, 2 = superficial damage or no scab on <25% of the nipple surface, 3 = superficial damage with or without scab on> 25% of nipple surface, 4 = partial thickness wound with or without scab on <25% of nipple surface, 5 = partial thickness with or without scab on> 25% of nipple surface.
Three and 7 days after applying the treatment, the condition of the nipple will be evaluated with a Questionnaire on Pain and Damage to the Nipple, where a telephone survey will be performed by the Principal Investigator in order to describe and compare the condition of the nipples.
- Assessment of breastfeeding self-efficacy [ Time Frame: baseline, 3 and 7 days post randomization ]Breastfeeding self-efficacy will be evaluated by a validated version of the Self-Efficacy Scale-Short Form (BSES-SF). The scale consists of 14 items, with the offered five statements on the Likert scale, from strongly disagree to strongly agree. The sum of grades ranges from 14 to 70, the higher the sum the greater the efficiency of breastfeeding.
- Breastfeeding duration and exclusivity. [ Time Frame: 3 and 7 days post randomization, 3 and 6 months postpartum ]The way of feeding of the baby in the last 24 hours will be evaluated by the World Health Organization (WHO) breastfeeding categories. The assessment will be conducted through a telephone interview with her mother.
- Satisfaction with proposed treatment [ Time Frame: 3 and 6 months postpartum ]The evaluation will be conducted by telephone interview with the Maternal Satisfaction

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Primiparas who have given birth to infants born at full term at between 37-41 weeks gestation
- Mothers complaint of nipple pain with any sign of nipple trauma to one or both nipples,
- Access to telephone
- Signed Informed consent
Exclusion Criteria:
- Primiparas with mental disorders
- Mothers allergy to lanolin
- Mothers with abnormal nipples
- Breast hypoplasia
- Infant with cleft palate
- Ankyloglossia
- Unsigned Informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04153513
Bosnia and Herzegovina | |
Department of Gynecology and Obstetrics, University Clinical Hospital Mostar | |
Mostar, HNŽ, Bosnia and Herzegovina, 88000 |
Principal Investigator: | Olivera Perić, VII | Department of Gynecology and Obstetrics, University Clinical Hospital Mostar | |
Study Chair: | Anita Pavičić Bošnjak, VII | Clinical Hospital Centre Zagreb | |
Study Chair: | Vajdana Tomić, VII | Department of Gynecology and Obstetrics, University Clinical Hospital Mostar |
Publications of Results:
Responsible Party: | Olivera Perić, Olivera Perić MSc, Head nurse Department of Gynecology and Obstetrics, University of Mostar |
ClinicalTrials.gov Identifier: | NCT04153513 |
Other Study ID Numbers: |
Study 2 |
First Posted: | November 6, 2019 Key Record Dates |
Last Update Posted: | February 16, 2021 |
Last Verified: | February 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | All of the individual participant data collected during the trial, after deidentification. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code |
Time Frame: | Beginning 3 months and ending 5 years following article publication. |
Access Criteria: | Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |